Merck-Schering Merger Requires Divestiture of Phase II Antiemetic Due To Emend's Strength
This article was originally published in The Pink Sheet Daily
Executive SummaryFTC says Schering must divest its NK-1 receptor antagonist relapitant. Merck must also sell its interest in a $2.6 billion animal health joint venture.
You may also be interested in...
The third biotech company to be spun out of GlaxoSmithKline’s unwanted neurosciences R&D is NeRRe Therapeutics, which has a neurokinin antagonist ready for Phase II clinical studies in an undisclosed indication.